S.M.A.I.O Future Growth
Future criteria checks 5/6
S.M.A.I.O is forecast to grow earnings and revenue by 103.8% and 27.6% per annum respectively. EPS is expected to grow by 103.6% per annum. Return on equity is forecast to be 11.1% in 3 years.
Key information
103.8%
Earnings growth rate
103.6%
EPS growth rate
| Medical Equipment earnings growth | 15.4% |
| Revenue growth rate | 27.6% |
| Future return on equity | 11.1% |
| Analyst coverage | Low |
| Last updated | 16 Oct 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 13 | 2 | 0 | 2 | 1 |
| 12/31/2025 | 10 | 1 | -2 | 0 | 1 |
| 12/31/2024 | 5 | -2 | -3 | -1 | 1 |
| 6/30/2024 | 7 | -1 | -3 | -2 | N/A |
| 3/31/2024 | 8 | 0 | -2 | -1 | N/A |
| 12/31/2023 | 9 | 1 | -1 | 0 | N/A |
| 9/30/2023 | 7 | 0 | -1 | 0 | N/A |
| 6/30/2023 | 6 | -1 | -1 | 0 | N/A |
| 3/31/2023 | 5 | 1 | 2 | 3 | N/A |
| 12/31/2022 | 3 | 3 | 5 | 6 | N/A |
| 9/30/2022 | 3 | 3 | 5 | 6 | N/A |
| 6/30/2022 | 3 | 4 | 5 | 6 | N/A |
| 3/31/2022 | 3 | 0 | 1 | 2 | N/A |
| 12/31/2021 | 3 | -3 | -4 | -3 | N/A |
| 9/30/2021 | 3 | -3 | N/A | N/A | N/A |
| 6/30/2021 | 3 | -3 | N/A | N/A | N/A |
| 3/31/2021 | 2 | -2 | N/A | N/A | N/A |
| 12/31/2020 | 2 | -2 | -5 | -3 | N/A |
| 12/31/2019 | 1 | -2 | -1 | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALSMA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.4%).
Earnings vs Market: ALSMA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ALSMA is expected to become profitable in the next 3 years.
Revenue vs Market: ALSMA's revenue (27.6% per year) is forecast to grow faster than the French market (5.6% per year).
High Growth Revenue: ALSMA's revenue (27.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ALSMA's Return on Equity is forecast to be low in 3 years time (11.1%).